AstraZeneca PLC Detailed Financials
Full historical quarterly statements
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-30 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 15.19B | 15.29B | 15.50B | 15.19B | 14.46B | 13.59B | 14.89B | 13.56B |
| Cost of Goods Sold | 4.02B | 2.68B | 3.12B | 2.80B | 2.47B | 2.24B | 2.73B | 3.08B |
| Gross Profit | 11.18B | 12.61B | 12.38B | 12.39B | 11.98B | 11.35B | 12.17B | 10.48B |
| R&D Expenses | 3.62B | 3.49B | 3.86B | 3.66B | 3.55B | 3.16B | 4.68B | 3.12B |
| Operating Expenses | 8.10B | 8.36B | 9.41B | 8.81B | 8.48B | 7.67B | 10.13B | 8.38B |
| Operating Income | 3.07B | 4.25B | 2.98B | 3.58B | 3.51B | 3.67B | 2.04B | 2.11B |
| Other Income / Gains | -309.1M | -332.0M | -349.0M | -339.0M | -381.0M | -272.0M | -370.0M | -278.0M |
| Net Income | 2.48B | 3.08B | 2.33B | 2.53B | 2.45B | 2.92B | 1.50B | 1.43B |
| EPS (Diluted) | 3.20 | 3.98 | 3.02 | 3.26 | 3.16 | 3.76 | 1.94 | 1.84 |
| Reported Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Gross Profit Ratio | 0.736 | 0.825 | 0.799 | 0.816 | 0.829 | 0.835 | 0.817 | 0.773 |
| General And Administrative Expenses | 5.65B | 4.92B | 5.49B | 5.08B | 4.86B | 4.49B | 5.41B | 5.14B |
| Selling And Marketing Expenses | 145.0M | 141.0M | 153.0M | 148.0M | 143.0M | 135.0M | 143.0M | 145.0M |
| Selling General And Administrative Expenses | 4.49B | 5.06B | 5.64B | 5.23B | 5.01B | 4.63B | 5.55B | 5.29B |
| Other Expenses | -1K | -189.0M | -100.0M | -89.0M | -79.0M | -113.0M | -100.0M | -25.0M |
| Cost And Expenses | 12.12B | 11.04B | 12.53B | 11.61B | 10.95B | 9.91B | 12.86B | 11.46B |
| Interest Income | 79.0M | 73.0M | 123.0M | 85.0M | 68.0M | 84.0M | 64.0M | 183.0M |
| Interest Expense | 429.6M | 393.0M | 472.0M | 434.0M | 439.0M | 349.0M | 429.0M | 457.0M |
| Depreciation And Amortization | 1.91B | 1.37B | 1.51B | 1.55B | 1.39B | 1.28B | 714.0M | 1.82B |
| Ebitda | 4.98B | 5.67B | 4.61B | 5.23B | 4.96B | 5.04B | 2.81B | 4.10B |
| Ebitdaratio | 0.328 | 0.371 | 0.297 | 0.344 | 0.343 | 0.371 | 0.189 | 0.302 |
| Operating Income Ratio | 0.202 | 0.278 | 0.192 | 0.236 | 0.243 | 0.27 | 0.137 | 0.155 |
| Income Before Tax | 2.76B | 3.91B | 2.63B | 3.24B | 3.13B | 3.40B | 1.67B | 1.83B |
| Income Before Tax Ratio | 0.182 | 0.256 | 0.17 | 0.214 | 0.216 | 0.25 | 0.112 | 0.135 |
| Income Tax Expense | 287.4M | 833.0M | 300.0M | 709.0M | 679.0M | 481.0M | 166.0M | 395.0M |
| Net Income Ratio | 0.163 | 0.201 | 0.15 | 0.167 | 0.169 | 0.215 | 0.101 | 0.105 |
| Epsdiluted | 3.18 | 3.94 | 2.96 | 3.24 | 3.14 | 3.74 | 1.92 | 1.82 |
| Weighted Average Shs Out | 775.5M | 774.5M | 775.0M | 781.8M | 775.0M | 775.0M | 775.0M | 777.0M |
| Weighted Average Shs Out Dil | 780.0M | 780.5M | 781.0M | 780.5M | 779.5M | 780.5M | 781.0M | 780.0M |